Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

被引：125

作者：

Martinez, Carmen ^{[1
,6
]}

Gayoso, Jorge ^{[4
]}

Canals, Carmen ^{[2
]}

Finel, Herve ^{[6
]}

Peggs, Karl ^{[10
]}

Dominietto, Alida ^{[16
]}

Castagna, Luca ^{[17
]}

Afanasyev, Boris ^{[20
]}

Robinson, Stephen ^{[13
]}

Blaise, Didier ^{[7
]}

Corradini, Paolo ^{[18
]}

Itala-Remes, Maija ^{[21
]}

Bermudez, Arancha ^{[5
]}

Forcade, Edouard ^{[8
]}

Russo, Domenico ^{[19
]}

Potter, Michael ^{[11
]}

McQuaker, Grant ^{[14
]}

Yakoub-Agha, Ibrahim ^{[9
]}

Scheid, Christof ^{[22
]}

Bloor, Adrian ^{[15
]}

Montoto, Silvia ^{[6
,12
]}

Dreger, Peter ^{[6
,23
]}

Sureda, Anna ^{[3
,6
]}

机构：

[1] Hosp Clin Barcelona, Inst Hematol & Oncol, Barcelona, Spain

[2] Banc Sang & Teixits, Barcelona, Spain

[3] Hosp Duran & Reynals, Inst Catal Oncol, Barcelona, Spain

[4] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[5] Hosp Univ Marques Valdecilla, Cantabria, Spain

[6] European Soc Blood & Marrow Transplantat, Paris, France

[7] Inst Paoli Calmettes, Marseille, France

[8] Univ Hosp Bordeaux, Bordeaux, France

[9] CHRU Lille, Lille Inflammat Res Int Ctr, Inst Natl Sante & Rech Med, U995, Lille, France

[10] UCL, Canc Inst, London, England

[11] Royal Marsden Hosp, London, England

[12] St Bartholomews Hosp, Barts Hlth Natl Hlth Serv Trust, London, England

[13] Bristol Haematol & Oncol Ctr, Bristol, Avon, England

[14] Gartnavel Royal Hosp, Glasgow, Lanark, Scotland

[15] Christie Natl Hlth Serv Trust Hosp, Manchester, Lancs, England

[16] Azienda Osped Univ San Martino IST, Ist Ricovero & Cura Carattere Sci Oncol, Genoa, Italy

[17] Ist Clin Humanitas, Milan, Italy

[18] Ist Nazl Tumori, Milan, Italy

[19] Univ Brescia, Brescia, Italy

[20] First Pavlov State Med Univ St Petersburg, St Petersburg, Russia

[21] Turku Univ Hosp, Turku, Finland

[22] Univ Cologne, Cologne, Germany

[23] Heidelberg Univ, Heidelberg, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 30期

关键词：

STEM-CELL TRANSPLANTATION; RELAPSE-FREE SURVIVAL; VERSUS-HOST-DISEASE; HEMATOLOGIC MALIGNANCIES; ALLOGENEIC TRANSPLANTATION; INTENSITY; OUTCOMES; EXPERIENCE; LEUKEMIA; REGIMEN;

D O I：

10.1200/JCO.2017.72.6869

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation. Results Median follow-up of survivors was 29 months. No differences were observed between groups in the incidence of acute graft-versus-host disease (GVHD). HAPLO was associated with a lower risk of chronic GVHD (26%) compared with MUD (41%; P =.04). Cumulative incidence of nonrelapse mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and corresponding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%, respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO (P =.26) and higher in MUD (P =.003), and risk of relapse was lower in both HAPLO (P =.047) and MUD (P,.001). Two-year overall survival and progression-free survival were 67% and 43% for HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no significant differences in overall survival or progression-free survival between HAPLO and SIB or MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival was significantly better for HAPLO (40%) compared with SIB (28%; P =.049) and similar to MUD (38%; P =.59). Conclusion Post-transplantation cyclophosphamide-based HAPLO transplantation results in similar survival outcomes compared with SIB and MUD, which confirms its suitability when no conventional donor is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD transplantation. (C) 2017 by American Society of Clinical Oncology

引用

页码：3425 / +

页数：11

共 31 条

[1] Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma:: Results of a Spanish prospective cooperative protocol [J].

Alvarez, I ;

Sureda, A ;

Caballero, MD ;

Urbano-Ispizzua, A ;

Ribera, JM ;

Canales, M ;

García-Conde, J ;

Sanz, G ;

Arranz, R ;

Bernal, MT ;

de la Serna, J ;

Díez, JL ;

Moraleda, JM ;

Rubió-Félix, D ;

Xicoy, B ;

Martínez, C ;

Mateos, MV ;

Sierra, J .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) :172-183

[2] Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen [J].

Anderlini, P ;

Saliba, R ;

Acholonu, S ;

Okoroji, GJ ;

Donato, M ;

Giralt, S ;

Andersson, B ;

Ueno, NT ;

Khouri, I ;

De Lima, M ;

Hosing, C ;

Cohen, A ;

Ippoliti, C ;

Romaguera, J ;

Rodriguez, MA ;

Pro, B ;

Fayad, L ;

Goy, A ;

Younes, A ;

Champlin, RE .

BONE MARROW TRANSPLANTATION, 2005, 35 (10) :943-951

[3] Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience [J].

Anderlini, Paolo ;

Saliba, Rima ;

Acholonu, Sandra ;

Giralt, Sergio A. ;

Andersson, Borje ;

Ueno, Naoto T. ;

Hosing, Chitra ;

Khouri, Issa F. ;

Couriel, Daniel ;

de Lima, Marcos ;

Qazilbash, Muzaffar H. ;

Pro, Barbara ;

Romaguera, Jorge ;

Fayad, Luis ;

Hagemeister, Frederick ;

Younes, Anas ;

Munsell, Mark F. ;

Champlin, Richard E. .

HAEMATOLOGICA, 2008, 93 (02) :257-264

[4] Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: Importance of histology for outcome [J].

Armand, Philippe ;

Kim, Haesook T. ;

Ho, Vincent T. ;

Cutler, Corey S. ;

Koreth, John ;

Antin, Joseph H. ;

LaCasce, Ann S. ;

Jacobsen, Eric D. ;

Fisher, David C. ;

Brown, Jennifer R. ;

Canellos, George P. ;

Freedman, Arnold S. ;

Soiffer, Rohert J. ;

Alyea, Edwin P. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (04) :418-425

[5] Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype [J].

Aversa, F ;

Tabilio, A ;

Velardi, A ;

Cunningham, I ;

Terenzi, A ;

Falzetti, F ;

Ruggeri, L ;

Barbabietola, G ;

Aristei, C ;

Latini, P ;

Reisner, Y ;

Martelli, MF .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) :1186-1193

[6] T-Cell-Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation [J].

Bashey, Asad ;

Zhang, Xu ;

Sizemore, Connie A. ;

Manion, Karen ;

Brown, Stacey ;

Holland, H. Kent ;

Morris, Lawrence E. ;

Solomon, Scott R. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) :1310-1316

[7] Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma [J].

Burroughs, Lauri M. ;

O'Donnell, Paul V. ;

Sandmaier, Brenda M. ;

Storer, Barry E. ;

Luznik, Leo ;

Symons, Heather J. ;

Jones, Richard J. ;

Ambinder, Richard F. ;

Maris, Michael B. ;

Blume, Karl G. ;

Niederwieser, Dietger W. ;

Bruno, Benedetto ;

Maziarz, Richard T. ;

Pulsipher, MichaelA. ;

Petersen, Finn B. ;

Storb, Rainer ;

Fuchs, Ephraim J. ;

Maloney, David G. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (11) :1279-1287

[8] Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas [J].

Castagna, L. ;

Bramanti, S. ;

Furst, S. ;

Giordano, L. ;

Crocchiolo, R. ;

Sarina, B. ;

Mauro, E. ;

Morabito, L. ;

Bouabdallah, R. ;

Coso, D. ;

Balzarotti, M. ;

Broussais, F. ;

El-Cheikh, J. ;

Stella, C. C. ;

Brusamolino, E. ;

Blaise, D. ;

Santoro, A. .

BONE MARROW TRANSPLANTATION, 2014, 49 (12) :1475-1480

[9]

Castagna L, 2017, BONE MARROW TRANSPL, V1, P1

[10] Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia [J].

Ciurea, Stefan O. ;

Zhang, Mei-Jie ;

Bacigalupo, Andrea A. ;

Bashey, Asad ;

Appelbaum, Frederick R. ;

Aljitawi, Omar S. ;

Armand, Philippe ;

Antin, Joseph H. ;

Chen, Junfang ;

Devine, Steven M. ;

Fowler, Daniel H. ;

Luznik, Leo ;

Nakamura, Ryotaro ;

O'Donnell, Paul V. ;

Perales, Miguel-Angel ;

Pingali, Sai Ravi ;

Porter, David L. ;

Riches, Marcie R. ;

Ringden, Olle T. H. ;

Rocha, Vanderson ;

Vij, Ravi ;

Weisdorf, Daniel J. ;

Champlin, Richard E. ;

Horowitz, Mary M. ;

Fuchs, Ephraim J. ;

Eapen, Mary .

BLOOD, 2015, 126 (08) :1033-1040

← 1 2 3 4 →